A	B	C	D	E	F	G
1	Main
2	INCB18424
3		Name	Company	Indication	Phase	Mechanism	Administration
4		CP-690,550	Pfizer, PFE	Rheumatoid Arthritis	II completed, II/III ongoing	JAK inhibitor	Oral
5		CP-690,550	Pfizer, PFE	Psoriasis	II ongoing	JAK inhibitor	Oral
6		CP-690,550	Pfizer, PFE	Psoriasis	II ongoing	JAK inhibitor	Topical
7		CP-690,550	Pfizer, PFE	Transplant Rejection	II completed, II ongoing	JAK inhibitor	Oral
8		CP-690,550	Pfizer, PFE	Crohn's Disease	II ongoing	JAK inhibitor	Oral
9		INCB18424	Incyte, INCY	Myelofibrosis	II ongoing, III planned	JAK 1/2 inhibitor, no JAK3 effect	Oral
10		INCB18424	Incyte, INCY	Rheumatoid Arthritis	II ongoing, II planned	JAK 1/2 inhibitor, no JAK3 effect	Oral
11		CEP-701	Cephalon, CEPH	PV/ET	II ongoing		Oral
12		TG101438	TargeGen	Myelofibrosis	I/II ongoing	JAK2 inhibitor	Oral
13		XL-019	Exelixis, EXEL	Polycythemia Vera	I ongoing		Oral
14		XL-019	Exelixis, EXEL	Myelofibrosis	I ongoing		Oral
15		VX-509	Vertex, VRTX	???	I ongoing	JAK3 inhibitor	Oral
16		Rigel	Rigel, RIGL
17		Cytopia
18		Abbott	Abbott, ABT
19		Supergen	Supergen, SUPG